Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
Clinical trial NCT04515238 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04515238
- Sponsor
- German CLL Study Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-01
- Primary completion
- 2027-02-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.